Liver stiffness measurement for risk assessment of hepatocellular carcinoma

Hepatology Research

Volumn 45, Issue 5, 2015, Pages 523-532

  Tatsumi, Akihisa ^a   Maekawa, Shinya ^a   Sato, Mitsuaki ^a   Komatsu, Nobutoshi ^a   Miura, Mika ^a   Amemiya, Fumitake ^b   Nakayama, Yasuhiro ^a   Inoue, Taisuke ^a   Sakamoto, Minoru ^a   Enomoto, Nobuyuki ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Kofu Municipal Hospital   (Japan)

Author keywords

FibroScan; Hepatocellular carcinoma; Liver fibrosis

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER GROWTH; CANCER RISK; CHRONIC LIVER DISEASE; CONTROLLED STUDY; ELASTOGRAPH; FEMALE; HEPATITIS C; HEPATOBILIARY PARAMETERS; HUMAN; LIVER CELL CARCINOMA; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFERENCE VALUE; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; THROMBOCYTE COUNT;

EID: 84928191372     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12377     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
2. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365 (12): 1118-1127.
3. Ikeda K, Saitoh S, Suzuki Y etal. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28 (6): 930-938.
4. Inoue A, Tsukuma H, Oshima A etal. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis. J Epidemiol 2000; 10 (4): 234-240.
5. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21 (3): 650-655.
6. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131 (3): 174-181.
7. Sandrin L, Fourquet B, Hasquenoph JM etal. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29 (12): 1705-1713.
8. Abenavoli L, Beaugrand M. Transient elastography in non-alcoholic fatty liver disease. Ann Hepatol 2012; 11 (2): 172-178.
9. Cardoso AC, Carvalho-Filho RJ, Marcellin P. Transient elastography in chronic viral hepatitis: a critical appraisal. Gut 2011; 60 (6): 759-764.
10. Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int 2011; 5 (2): 625-634.
11. Yoneda M, Mawatari H, Fujita K etal. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40 (5): 371-378.
12. Kim BK, Fung J, Yuen MF, Kim SU. Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol 2013; 19 (12): 1890-1900.
13. Akima T, Tamano M, Hiraishi H. Liver stiffness measured by transient elastography is a predictor of hepatocellular carcinoma development in viral hepatitis. Hepatol Res 2011; 41 (10): 965-970.
14. Jung KS, Kim SU. Clinical applications of transient elastography. Clin Mol Hepatol 2012; 18 (2): 163-173.
15. Jung KS, Kim SU, Ahn SH etal. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53 (3): 885-894.
16. Kuo YH, Lu SN, Hung CH etal. Liver stiffness measurement in the risk assessment of hepatocellular carcinoma for patients with chronic hepatitis. Hepatol Int 2010; 4 (4): 700-706.
17. Masuzaki R, Tateishi R, Yoshida H etal. Comparison of liver biopsy and transient elastography based on clinical relevance. Can J Gastroenterol 2008; 22 (9): 753-757.
18. Masuzaki R, Tateishi R, Yoshida H etal. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49 (6): 1954-1961.
19. Wang HM, Hung CH, Lu SN etal. Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients. Liver Int 2013; 33 (5): 756-761.
20. Boursier J, Zarski JP, de Ledinghen V etal. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology 2013; 57 (3): 1182-1191.
21. Castera L. Liver stiffness and hepatocellular carcinoma: liaisons dangereuses? Hepatology 2009; 49 (6): 1793-1794.
22. Chon YE, Choi EH, Song KJ etal. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One 2012; 7 (9): e44930.
23. Lupsor M, Badea R, Stefanescu H etal. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. J Gastrointestin Liver Dis 2008; 17 (2): 155-163.
24. Wong VW, Vergniol J, Wong GL etal. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51 (2): 454-462.
25. Masuzaki R, Tateishi R, Yoshida H etal. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol 2008; 42 (7): 839-843.
26. de Oliveria Andrade LJ, D'Oliveira A, Melo RC, De Souza EC, Costa Silva CA, Parana R. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis 2009; 1 (1): 33-37.
27. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002; 36 (5 Suppl 1): S74-83.
28. Asahina Y, Tsuchiya K, Nishimura T etal. alpha-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. Hepatology 2013; 58 (4): 1253-1262.
29. Asahina Y, Tsuchiya K, Tamaki N etal. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52 (2): 518-527.
30. Lewis S, Roayaie S, Ward SC, Shyknevsky I, Jibara G, Taouli B. Hepatocellular carcinoma in chronic hepatitis C in the absence of advanced fibrosis or cirrhosis. AJR Am J Roentgenol 2013; 200 (6): W610-616.
31. Arase Y, Kobayashi M, Suzuki F etal. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology 2013; 57 (3): 964-973.
32. Reddy SK, Steel JL, Chen HW etal. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012; 55 (6): 1809-1819.
33. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51 (5): 1820-1832.
34. Kudo M, Izumi N, Kokudo N etal. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29 (3): 339-364.